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routine service cost, and cost of adverse event treatment. RESULTS: EGFR-TKI treat-
ment provided a better progression-free survival and overall survival compared with 
docetaxel. Except rash, dry skin and dry eyes, the incidence of other adverse events 
in patients treated with EGFR-TKI was lower than docetaxel. However, the monthly 
treatment cost and total treatment costs of EGFR-TKI were higher than docetaxel at 
37,017.55 baht/month and 451,071.08 baht respectively. The incremental cost-effec-
tiveness ratio (ICER) was 631,426.01 baht/life-year-gained (LYG). CONCLUSIONS: 
Though EGFR-TKI has a more favorable clinical outcome than docetaxel, the addi-
tional cost per LYG is signiﬁ cant. This ICER is greater than the threshold suggested 
by the WHO, three times of GDP/capita (300,000 baht), which may consider to be 
not cost-effective. Both docetaxel and EGFR-TKI are the effective and available treat-
ments for aNSCLC in Thailand. When making a decision and policy regarding the 
treatments of aNSCLC, this economic evidence should be taken into account along 
with other clinical aspects. 
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OBJECTIVES: Cetuximab, a monoclonal antibody directed against the epidermal 
growth factor receptor, improves progression free survival and overall survival for 
metastatic colorectal cancer (mCRC) patients. However patients with K-ras mutation 
don’t beneﬁ t from cetuximab. METHODS: We performed cost-effectiveness analysis 
of K-ras testing and cetuximab treatment as last-line therapy for mCRC patients. In 
our analysis, we considered three groups: A) cetuximab treatment for patients with 
wild-type tumors and best supportive care (BSC) for mutant patients with K-ras 
testing; B) cetuximab treatment for all the patients without K-ras testing; and C) BSC 
for all the patients without K-ras testing. The cost-effectiveness of three comparison 
groups was calculated: group A versus B (cost-effectiveness of K-ras testing), group A 
versus C (cost-effectiveness of cetuximab treatment with K-ras testing), and group B 
versus C (cost-effectiveness of cetuximab treatment without K-ras testing). Con-
structed three-state Markov model was used to predict expected costs and outcome 
of each group. Outcome was based on the report by Karapetis et al. (2008), who 
retrospectively analyzed NCIC CTG CO. 17. Only direct medical costs were included 
from the perspective of Japanese health-care payer. Three percent discount rate was 
used for both costs and outcome. RESULTS: K-ras testing for cetuximab treatment 
reduced costs by JPY 500,000 per patients. Budget impact was estimated to be JPY 3 
to 5 billion. However, the ICER of cetuximab with K-ras testing was more than JPY 
10 million per life-year gained (LYG) although it was smaller than ICER of cetuximab 
without K-ras testing. Even if the mean utility score was 0.7, the ICER was approach-
ing JPY 20 million per QALY. CONCLUSIONS: When the cetuximab treatment is 
administered as last-line therapy for mCRC patients, K-ras testing is recommended. 
However, the ICER of cetuximab treatment is too high, even if the treatment is limited 
to patients with wild-type K-ras. 
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OBJECTIVES: To elucidate the more cost-effective dosing strategy for the administra-
tion of pemetrexed in the second-line treatment of patients having been treated for 
advanced non-small cell lung cancer (NSCLC). METHODS: Validation of the model 
was based on efﬁ cacy and safety data from a phase II clinical study conducted in Japan 
of two pemetrexed doses: 500 mg/m2 (P500) versus 1000 mg/m2 (P1000). Cost-effec-
tiveness and cost-minimization analyses were performed to estimate the impact of 
P500 versus P1000 on expected life-years and costs from the perspective of the Japa-
nese national health insurance (NHI) system. Costs covered additional treatment and 
test which are needed due to the treatment of pemetrexed and adverse events. A sub-
group analysis was conducted to compare the cost-effectiveness of pemetrexed in 
patients with different NSCLC histologies. RESULTS: P1000 exhibited a negative 
life-years gained (LYG) of −0.115 at an incremental cost of US$13,674 compared to 
P500, implying simple dominance of P500 over P1000. The incremental cost-effec-
tiveness ratio (ICER) of pemetrexed therapy with P500 was estimated at US$19,479/
LYG, compared with the same therapy in squamous cell carcinoma, when it is per-
formed in non-squamous cell carcinoma. Results of a probabilistic sensitivity analysis 
demonstrated an almost 100% likelihood of the ICER of pemetrexed with P500 for 
non-squamous cell patients falling below the threshold of US$50,000/LYG. CON-
CLUSIONS: P500 is a more cost-effective dosing regimen than P1000 for pemetrexed 
chemotherapy in patients with NSCLC. Also, results suggest that pemetrexed is more 
cost-effective in NSCLC patients of non-squamous histology than of squamous histol-
ogy from the payer’s perspective. 
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OBJECTIVES: To determine the economic implications of agents used to treat meta-
static renal cell carcinoma (mRCC). METHODS: A lifetime Markov model was 
developed to simulate the patterns of disease progression and to determine the out-
comes under treatment of available medicines including interferon-alpha (IFNa), suni-
tinib, sorafenib, and bevacizumab. Costs were measured based on the perspective of 
a health-care provider. Resource utilization derived from retrospective chart reviews 
of 14 mRCC patients treated at the King Chulalongkorn Memorial Hospital, Bangkok, 
Thailand. Costs and survival beneﬁ ts were discounted annually at 3%. RESULTS: 
The major assumption of the study was that the projected PFS and overall survival 
were longer for sunitinib than the other comparative treatments based on results of 
published studies. Additional treatment after failure of one tyrosine kinase inhibitor 
(TKI) in the model was limited which ﬁ t well with the practical scenario in developing 
country. Cost-effectiveness analyses demonstrated that IFNa had the most favorable 
cost-effectiveness ratio at 1.3 million Baht/QALYs followed by sunitinib, sorafenib, 
and bevacizumab at 1.7, 1.9, 9.3 million Baht/QALYs respectively. However, sunitinib 
had a better incremental cost-effectiveness ratios (ICERs) over IFNa at 2.0 million 
Baht/PFY, 2.7 million Baht/LYG, and 3.6 million Baht/QALY gained. Sensitivity 
analysis showed that the most sensitive parameters for sunitinib were the overall 
survival efﬁ cacy and costs. CONCLUSIONS: Our study reveals that sunitinib has the 
good cost-effectiveness proﬁ les as one of the ﬁ rst line treatment of mRCC. With 
current study model, it may be applicable to the situation in developing country with 
limit availability of TKIs in the treatment of mRCC. However, sunitinib’s ICER 
comparing to IFNa is still beyond the ICER threshold for a developing country. This 
cost-effectiveness evidence should be taken into account in conjunction with other 
clinical, societal and ethical considerations in the treatment of mRCC. 
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OBJECTIVES: Colorectal cancer (CRC) is one of the most common forms of cancer 
in western countries and represents the second leading cause of cancer mortality in 
Europe (AIRTUM, 2009). Early detection and removal of cancerous lesions can reduce 
the incidence of CRC, its mortality and improve patients’ quality of life (Taupin et al. 
2006). The main literature on this topic refers to USA and few studies have been 
conducted in Italy to date (Zappa et al. 1997; Tappenden et al. 2007). Aim of the 
paper is to shed some light on the effectiveness and costs of screening programs in the 
Italian health-care system, presenting the results of a cost-effectiveness analysis of a 
CRC screening program in Italy. METHODS: We use as case-study a Regional CRC 
screening program to determine the full costs and the effectiveness of the adopted 
techniques, FOBT combined with colonoscopy. The costs involved in each phase of 
the program are evaluated using a micro-costing analysis. Effectiveness is valued in 
terms of early detected lesions and years of life gained. Cost and effectiveness data 
are used to estimate the costs for year of life gained, using a MISCAN-COLON 
Model© to simulate and compare two alternative scenarios, with or without the 
screening program. RESULTS: The preliminary results show that the screening will 
prevent almost 2.0 deaths (11.2%) per 1000 screened individuals, corresponding to 
19.4 years of life gained in 30 years with an incremental cost effectiveness ratio of 
f2400 for life-year gained. CONCLUSIONS: The results outpace those of previous 
studies (Sonnenberg, 2000), signalling an increasing effectiveness of CRC screening 
program. Besides, the paper highlights the importance of implementing a screening 
not only for the effects that prevention can have in clinical terms, but also for the 
economic impact of such a policy in relation to the long-term sustainability of health-
care systems. 
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OBJECTIVES: This study aims to evaluate the cost-effectiveness of two aromatase 
inhibitors for adjuvant treatment of postmenopausal hormone receptor positive early 
breast cancer, and to address the most reasonable treatment option when population 
is stratiﬁ ed by nodal status. METHODS: A Markov model was developed deﬁ ning 
six Markov states based on breast cancer progression. Annual probabilities of recur-
rence by adjuvant treatment, anastrozole, letrozole, and tamoxifen were estimated 
from published studies in overall population, node negative, and node positive group. 
Costs of deﬁ ned breast cancer events were measured by micro-costing methods based 
on 2009 National Health Insurance Fee Schedule and the third Clinical Guideline of 
Breast Cancer Treatment. Anastrozole and letrozole were compared with tamoxifen, 
respectively, using the same Markov model. Incremental cost-effectiveness ratios 
(ICERs) in overall population and each subgroup were estimated. RESULTS: When 
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anastrozole was compared with tamoxifen, anastrozole was more effective and costly 
than tamoxifen costing additional KRW 22,461,689 per QALY. Letrozole showed 
similar incremental cost of KRW 21,004,142 per QALY. In the node negative group, 
anastrozole was the most cost-effective with incremental cost of KRW 19,717,770 per 
QALY, while letrozole was the most cost-effective with incremental cost of KRW 
8,150,512 per QALY in node positive group. Sensitive analysis showed that these 
results were robust. CONCLUSIONS: Subgroup analysis clearly demonstrated which 
treatment was superior among aromatase inhibitors. Such a demonstration was not 
conﬁ rmative in the cases of overall population. The implication of this study is that 
the decision maker should be careful when generalizing the cost-effectiveness results. 
The stratiﬁ ed analysis in this context may help reach a reasonable decision on resource 
allocation. 
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OBJECTIVES: The objective of the study was to examine the direct medical cost of 
XELOX (capecitabine plus oxaliplatin) compared to FOLFOX (ﬂ uorouracil/leucovo-
rin plus oxaliplatin) for the treatment of advanced gastric cancer in China. METHODS: 
Since the equal efﬁ cacy was already demonstrated by the published literature and local 
clinical guideline, cost minimization analysis was performed to compare the direct 
medical costs of XELOX and FOLFOX for the treatment of advanced gastric cancer. 
The direct medical costs were associated with the drug costs, drug administration 
costs, hospitalization costs and adverse events management costs. The costs were 
calculated based on a questionnaire survey from a clinical expert panel of 20 gastro-
intestinal surgeons and medical oncologists. RESULTS: According to the result of 
clinical expert panel survey, the median treatment duration of XELOX and FOLFOX 
was six cycles and nine cycles, respectively. The drug cost of XELOX regimen was 
CNY 33,948 (US$4992), higher than FOLFOX by CNY 14,160 (US$2082). However, 
the cost increment of XELOX regimen was offset by the higher drug administration 
cost (deviation CNY 9985), hospitalization cost (deviation CNY 4734) and adverse 
events management cost (deviation CNY 1828) of FOLFOX regimen. As a result, 
XELOX showed a signiﬁ cant overall cost savings of CNY 2386 (US$351) compared 
with FOLFOX. CONCLUSIONS: According to the study, XELOX is cost saving in 
comparison with FOLFOX for the treatment of advanced gastric cancer in China, 
especially in the chemotherapy administration and hospitalization utilization. 
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OBJECTIVES: To estimate the clinical and economic effect of Liquid-Based Cytology 
(LBC) compared with Conventional Papanicolaou Smear (CP) screening program in 
Taiwan. METHODS: A decision analytic model was used to simulate the natural 
history of cervical cancer in Taiwan health-care system. This study adopts a Ministry 
of Health perspective in cost-effectiveness analysis to compare a CP strategy every 
year with eight different screening strategies. These strategies comprise three screening 
tools (CP, LBC with Filter Base Technology, and LBC with Cell Enrichment Technol-
ogy), and three screening intervals (annually, every 3 years, and every 5 years). Out-
comes are life expectancy, quality-adjusted life-years (QALYs), lifetime costs, and 
incremental cost-effectiveness ratios (ICER). Future costs and QALYs were discounted 
at an annual rate of 3%. One-way sensitivity analyses are conducted to assess param-
eter uncertainty. RESULTS: Compared with the current screening strategy (an annual 
CP), LBC with Filter Base Technology and LBC with Cell Enrichment Technology 
strategies every 3 or 5 years are less costly while the QALYs lost are trivial. When 
three times GDP per capita is used as the decision threshold, switching cervical cancer 
screening tools from Pap annually to LBC with Filter Base Technology annually 
strategy or LBC with Cell Enrichment Technology annually strategy are cost-effective, 
with ICER equaling NT$233,000 or NT$272,000 per QALY gained, respectively. 
CONCLUSIONS: Results from this study showed that it may be desirable to adopt 
LBC as primary screening tool and may to extend screening interval annually to every 
3 or 5 years in cervical cancer prevention. 
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OBJECTIVES: Sexually-transmitted Human PapillomaVirus (HPV) is the major cause 
of cervical cancer. For its greatest beneﬁ t, HPV vaccine is recommended for young 
girls before there is a possible exposure to HPV through sexual contacts. To assessing 
the potential beneﬁ ts of HPV vaccination program, it is crucial to collect the compre-
hensive information of infectious status and sexual behavior among adolescents. This 
study aims to implement the simulation technique to overcome the information barrier 
in Taiwan. METHODS: A population-based decision analytic model was established 
to simulate the health histories of 15 birth cohorts till they are aged 12 to 26. In the 
starting-point of simulation, these cohorts are aggregated to form a fully representative 
population in 2009. To capture the potential effects of catch-up vaccination programs, 
we computed the initial distribution of health states among each cohort by Markov 
model with cervical cancer natural history in Taiwanese women. We further validated 
the model by comparing the actual epidemiologic data and simulated results. The 
model was applied to estimate the incremental cost-effectiveness ratio (ICER) of 
the different vaccination programs from the perspective of health care. RESULTS: The 
simulated age patterns of HPV prevalence was corresponding to the observed age 
patterns of sexual experience. Based on the model, we found that inclusion of a HPV 
vaccination program for the cohort aged 12 can be considered as cost-effective (ICER 
value 1,010,000 NTD/QALY) comparing with annual Pap smear program only. 
Catch-up vaccination program for the cohorts aged 12–26 can be considered cost-
effective (ICER value 570,000 to 1,300,000 NTD/QALY) comparing with no inter-
vention. Results of sensitivity analysis suggest the robustness of the analysis. 
CONCLUSIONS: We have developed a model incorporating the local health and 
medical conditions. The population-based model is helpful for assessing a complicated 
public policy involved several generations. It provides plentiful information for esti-
mating the beneﬁ ts and budget impact of public policy. 
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OBJECTIVES: Lung cancer has a high mortality and is associated with a substantial 
ﬁ nancial burden. Cost-effectiveness estimated from foreign studies are usually not 
directly comparable between countries without adapting by applying the appropriate 
national value set. This study was performed to evaluate the cost-effectiveness of 
erlotinib versus docetaxel in patients with advanced non small cell lung cancer(NSCLC) 
who have failed previous chemotherapy in Korea. METHODS: A Markov model 
simulated to access the clinical and economic impact of erlotinib or docetaxel over 2 
years from society perspective. Progression free survival(PFS) and overall survival(OS) 
data were derived from clinical trials, and utility/disutility data were collected in 
published study. Life-year gained(LYG) is projected based on clinical outcomes and 
converted to quality-adjusted life-years (QALYs) by utility weight. Both direct medical 
costs (e.g., drugs, visits, monitoring, etc. ) and nonmedical costs were calculated. Costs 
and outcomes were discounted at an annual rate of 5% and incremental cost-effec-
tiveness ratio (ICER) consists of the difference in cost divided by the difference in 
QALYs. We performed sensitivity analysis to evaluate uncertainty in the results. 
RESULTS: After 2 years follow-up, the total costs per patient was lower with 
erlotinib(11,234,900KRW, 1USD = 1156.53KRW as of February 2010) than with 
docetaxel (12,105,719KRW). More QALY per patient would be obtained with erlo-
tinib than with docetaxel (0.268 and 0.213, respectively). Thus, ICER for erlotinib 
compared to Docetaxel is −15,829,756KRW per QALY. The results of the sensitivity 
analysis showed no signiﬁ cant difference. CONCLUSIONS: This study suggests, with 
its underlying assumptions and data, the use of erlotinib as second- or third-line treat-
ment for advanced NSCLC would not only save costs but also improve outcomes 
compared with docetaxel in Korea. 
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BACKGROUND: CML accounts for 15% of adult leukemia, with incidence ~1 per 
100,000. Imatinib mesylate is an oral medication for chronic phase (CP), accelerated 
phase, or blast crisis phase of CML. For CML patients showing resistance to imatinib, 
dose escalation is a treatment option. Nilotinib is a second generation tyrosine kinase 
inhibitor (TKI), rationally designed to preferentially target BCR-ABL, and has dem-
onstrated efﬁ cacy and safety in patients resistant or intolerant to imatinib. OBJEC-
TIVES: To estimate the total treatment costs and quality-adjusted life-years (QALY) 
gained for patients receiving high-dose imatinib (HDI) ≥600 mg/day because of resis-
tance or nilotinib 800 mg/day using a Markov model to project long-term outcome. 
METHODS: Model parameters were obtained from medical records of patients 
treated with HDI in Taiwan, along with published clinical trial data for HDI and 
nilotinib, and local drug and treatment costs. RESULTS: At the end of July, 2008, 45 
patients who have received imatinib ≥600 mg/day were included in the study and their 
charts were reviewed. During the entire treatment period of HDI and nilotinib, anemia 
was the most common treatment-related adverse event (22.2% vs. 15.6%). The model 
projected longer expected life-years gained by patients receiving nilotinib therapy 
(11.72 years vs. 9.31 years), and patients treated with nilotinib are expected to experi-
ence longer QALY than HDI (9.6 years vs. 7.47 years). Estimated cost per QALY was 
1,189,150 (NTD/year) for nilotinib and 1,169,547 (NTD/year) for HDI. CONCLU-
SIONS: Under the assumption of similar drug price for nilotinib and HD imatinib, 
the beneﬁ t of using nilotinib is obvious for the better clinical outcome achieved in 
terms of lower adverse event rate, better QALY, with acceptable economic impact. 
